Arbutus Biopharma Corporation (NASDAQ:ABUS) has been given an average recommendation of “Buy” by the six brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $21.00.

A number of research firms recently commented on ABUS. Zacks Investment Research downgraded Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday, August 7th. Finally, Ladenburg Thalmann Financial Services began coverage on Arbutus Biopharma Corporation in a report on Friday, June 2nd. They issued a “buy” rating and a $32.00 price objective for the company.

Arbutus Biopharma Corporation (ABUS) traded up 2.9718% during midday trading on Wednesday, hitting $4.0159. 220,228 shares of the company traded hands. Arbutus Biopharma Corporation has a 12-month low of $2.35 and a 12-month high of $4.10. The stock’s market cap is $220.98 million. The stock has a 50 day moving average of $3.67 and a 200 day moving average of $3.35.

ILLEGAL ACTIVITY NOTICE: “Arbutus Biopharma Corporation (ABUS) Receives Average Rating of “Buy” from Brokerages” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/arbutus-biopharma-corporation-abus-receives-average-rating-of-buy-from-brokerages/1528322.html.

In related news, insider Michael J. Sofia sold 30,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the completion of the sale, the insider now owns 1,563,403 shares in the company, valued at $5,784,591.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. OxFORD Asset Management LLP increased its stake in shares of Arbutus Biopharma Corporation by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares during the period. Vanguard Group Inc. increased its stake in shares of Arbutus Biopharma Corporation by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Arbutus Biopharma Corporation during the second quarter valued at about $478,000. Bank of Montreal Can increased its stake in shares of Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 16,535 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares during the period. Institutional investors and hedge funds own 67.06% of the company’s stock.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.